Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
Emerg Microbes Infect
; 10(1): 1241-1243, 2021 Dec.
Article
en En
| MEDLINE
| ID: mdl-34092181
ABSTRACT
In this study, we show that BNT162b2 vaccine-elicited antibodies efficiently neutralize SARS-CoV-2 authentic viruses belonging to B.1, B.1.1.7, B.1.351, B.1.525 and P.1 lineages. Interestingly, the neutralization of B.1.1.7 and B.1.525 lineages was significantly higher, whereas the neutralization of B.1.351 and P.1 lineages was robust but significantly lower as compared to B.1 lineage. Following our findings, we consider that the BNT162b2 vaccine offers protection against the current prevailing variants of SARS-CoV-2.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Anticuerpos Neutralizantes
/
Vacunas contra la COVID-19
/
SARS-CoV-2
/
COVID-19
/
Anticuerpos Antivirales
Límite:
Humans
Idioma:
En
Revista:
Emerg Microbes Infect
Año:
2021
Tipo del documento:
Article
País de afiliación:
Italia